With over six years of experience as President US Injectables at Xellia Pharmaceuticals, Craig Boyd leads the US injectables business unit's strategic direction, growth, and performance. He has a proven P&L track record of achieving and exceeding financial targets and business objectives, driven by identifying and executing on high-potential opportunities in the US pharmaceutical market.

Craig brings over 20 years’ experience in various global pharmaceutical markets, working extensively in the US, Asia, Europe and Australia and across numerous product categories such as brands, biosimilars, devices, generics and specialty generics. Craig joined Xellia from his most recent role as Chief Commercial Officer at Envigo.

Previously he was the Executive Vice President of Mayne Pharma’s US specialty brands and prior to this Craig led global commercial sales functions at Hospira and Mylan. He also spent 10 years at Novartis as a senior commercial sales and marketing executive.